UnknownPhase 4NCT02231125
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chen Xiangmei
- Principal Investigator
- Xiangmei Chen, MD.& Ph.DDepartment of Nephrology,State Key Laboratory of Kidney Disease,National Clinical Research Center for Kidney Disease, Chinese PLA General Hospital
- Intervention
- Losartan(drug)
- Enrollment
- 1600 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2014 – 2017
Study locations (30)
- The First Hospital of Anhui Medical University, Hefei, Anhui, China
- The Second Hospital of Anhui Medical University, Hefei, Anhui, China
- Beijing Chao-yang Hospital, Beijing, Beijing Municipality, China
- China-Japan Friendship Hospital, Beijing, Beijing Municipality, China
- Chinese PLA General Hospital, Beijing, Beijing Municipality, China
- Dong Zhi Men Hospital of Beijing University of Chinese Medicine, Beijing, Beijing Municipality, China
- Guang An Men Hospital China Academy of Chinese Medical Sciences, Beijing, Beijing Municipality, China
- PLA Navy General Hospital, Beijing, Beijing Municipality, China
- The Second Artillery General Hospital Of Chinese People's Liberation Army, Beijing, Beijing Municipality, China
- Da Ping Hospital Of Third Military Medical University, Chongqing, Chongqing Municipality, China
- Yongchuan Hospital Of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Chinese People's Liberation Army No.180 Hospital, Quanzhou, Fujian, China
- Chinese People's Liberation Army No.174 Hospital, Xiamen, Fujian, China
- The First Hospital of Lanzhou University, Lanzhou, Gansu, China
- The Second Hospital of Lanzhou University, Lanzhou, Gansu, China
- +15 more locations on ClinicalTrials.gov
Collaborators
Jiangsu Suzhong Pharmaceutical Group Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02231125 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital